<DOC>
	<DOCNO>NCT01918176</DOCNO>
	<brief_summary>Fixed sequence , 2-period crossover study compare pharmacokinetic profile Palbociclib absence presence prior administration proton pump inhibitor Rabeprazole . The increased gastric pH achieve treatment multiple dos Rabeprazole might affect absorption process Palbociclib .</brief_summary>
	<brief_title>Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib ( PD-0332991 )</brief_title>
	<detailed_description />
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<criteria>Female subject nonchildbearing potential ; Healthy subject identify detailed medical history , full physical examination include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test . A positive urine drug screen , urine cotinine test alcohol breath test . Treatment investigational drug within 30 day 5 halflives precede first dose study medication . Use prescription nonprescription drug dietary supplement within 7 day 5 halflives prior first dose study medication . All antacid agent must discontinue 28 day prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Palbociclib</keyword>
	<keyword>PD-0332991</keyword>
	<keyword>Proton Pump Inhibitor</keyword>
	<keyword>DDI</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Rabeprazole</keyword>
</DOC>